J

Jazz Pharmaceuticals

Biopharmaceuticals focused on neuroscience and oncology

Senior Director - Taxation

Full-Time
$226.4k - $339.6k
Expert
Master's
Pennsylvania, USA+1 moreMore locations: California, USA
Remote
AccountingTax Accounting

About the job

Requirements
  • Extensive United States federal, state, and international tax experience, including ASC 740 tax accounting, compliance, tax planning, and audit support.
  • Experience managing external advisors and leading cross-functional tax projects, including mergers and acquisitions transactions and business integrations.
  • Experience with the United States tax code and state tax provisions.
  • A Master's degree in Taxation or a Certified Public Accountant credential.
Responsibilities
  • Oversee quarterly and annual ASC 740 tax provisioning, including uncertain tax positions and related financial statement disclosures, and ensure compliance for the United States group and accurate, timely completion of all tax returns.
  • Support the finance function for tax provisioning purposes.
  • Lead tax planning and structuring on projects where appropriate.
  • Work with Corporate Development, Finance, Legal, and external advisors on acquisitions, integrations, restructurings, and other strategic transactions.
  • Manage relationships with external tax advisors, including oversight of scope, deliverables, budgets, and tax projects.
  • Provide technical leadership on complex United States federal, state, and international tax matters, including Canada and Japan tax matters, tax planning, tax accounting, and business initiatives.
  • Maintain and enhance tax governance, internal controls, and SOX compliance processes supporting the Company's tax function.
  • Liaise with United States federal and state tax authorities, including managing tax audits.
  • Stay current on new United States tax laws and promote group familiarity with and identification of tax law changes affecting the company.
  • Manage the United States tax team.

About the company

Jazz Pharmaceuticals develops and markets therapies in neuroscience and oncology. Its products include Xyrem and the lower-sodium option Xywav for narcolepsy, Epidiolex for seizures in severe epilepsy, and oncology medicines Zepzelca for small cell lung cancer and Vyxeos for AML, with Epidiolex being cannabidiol-based. The company grows its portfolio through a mix of in-house R&D and strategic acquisitions that broaden its specialty-drug lineup and global reach. Its goal is to expand approved treatments and the pipeline to help patients with limited options by building a diversified, specialty-focused portfolio.

Company Size

1,001-5,000

Company Stage

IPO

Headquarters

Dublin, Ireland

Founded

2003

Get referred to Jazz Pharmaceuticals

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Q2 2026 revenue hit $1.21 billion; Jazz raised full-year guidance to $4.68 billion.
  • Actio's ABS-1230 adds first-in-class KCNT1 epilepsy upside after the September 15, 2026 close.
  • Oncology revenue exceeded $1 billion in 2025, driven by Zepzelca and Ziihera.

What critics are saying

  • Xywav faces Lupin, Teva, and Tris patent fights; generic entry threatens 2027 cash flow.
  • Xywav and EPIDIOLEX still dominate value; one patent loss or safety issue would crush earnings.
  • Jazz paid $820 million for Actio before registrational proof; ABS-1230 can still fail.

What makes Jazz Pharmaceuticals unique

  • Ziihera launched August 2026, targeting $3B-$5B across HER2-positive tumors.
  • EPIDIOLEX holds exclusivity into the late 2030s and now funds four new trials.
  • Xywav's low-sodium oxybate formulation keeps narcolepsy patients despite generic Xyrem pressure.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

Dental Insurance

Vision Insurance

401(k) Retirement Plan

Paid Vacation

Growth & Insights and Company News

Headcount

6 month growth

0%

1 year growth

1%

2 year growth

0%
Yahoo Finance
Sep 20th, 2026
Jazz Pharma raises zanidatamab peak sales target to $3B-$5B as oncology revenue hits $1B

Jazz Pharmaceuticals reported its oncology revenue surpassed $1 billion in 2025, marking a 32% year-over-year increase. The growth follows three recent product launches, including zanidatamab, Modeyso and Zepzelca's FORTE regimen. The company raised zanidatamab's estimated peak-sales opportunity to $3 billion-$5 billion. Jazz aims to increase HER2-directed treatment adoption in gastroesophageal cancer, where only 60% of eligible HER2-positive patients currently receive such therapy. Jazz estimates the US incidence of HER2-positive gastroesophageal adenocarcinoma at approximately 8,000 patients, with a labelled population of 3,000 to 4,000 patients. The company is also developing zanidatamab for biliary tract cancer, colorectal cancer, non-small cell lung cancer and breast cancer. Jazz maintains commercial investment whilst preserving financial flexibility for acquisitions across oncology, epilepsy and sleep disorders.

Yahoo Finance
Sep 11th, 2026
Jazz Pharmaceuticals stock climbs 29.7% but analysts warn of declining margins and weak returns

Jazz Pharmaceuticals' stock has risen 29.7% over the past six months, outpacing the S&P 500 by 17 percentage points to reach $240.49 per share. However, analysts point to concerning trends in the company's fundamentals. The company's adjusted operating margin has declined by 2.6 percentage points over five years, despite revenue growth that should have improved economies of scale. Its trailing 12-month adjusted operating margin stood at 41.7%. Additionally, Jazz Pharmaceuticals' five-year average return on invested capital was just 2.7%, below the typical cost of capital for healthcare companies. This suggests mediocre efficiency in deploying capital for growth. The stock currently trades at 9.6× forward price-to-earnings ratio. Analysts consider this valuation reasonable but believe the company's weakening fundamentals present downside risk.

StockTitan
Aug 27th, 2026
Jazz Pharmaceuticals prices upsized $1.1B exchangeable notes offering with $225M share repurchase

Jazz Pharmaceuticals has priced an upsized $1.1 billion private offering of 1.875% exchangeable senior notes due 2032, up from the previously announced $1.0 billion. The offering, conducted through its wholly-owned subsidiary Jazz Investments I Limited, is expected to close on 31 August 2026. The notes will mature on 15 September 2032 and are exchangeable at an initial rate of 2.8150 ordinary shares per $1,000 principal amount, equivalent to an exchange price of approximately $355.24 per share. This represents a 42.5% premium above the last reported sale price on 26 August 2026. The company will use net proceeds of approximately $1,079 million for general corporate purposes. Concurrently, Jazz Pharmaceuticals agreed to repurchase approximately $225 million of its ordinary shares from note purchasers at $249.29 per share, using existing cash on hand.

Yahoo Finance
Aug 26th, 2026
Jazz Pharmaceuticals launches Ziihera for HER2-positive cancer with $3B–$5B peak sales outlook

Jazz Pharmaceuticals has launched Ziihera in the US following FDA approval for first-line treatment of HER2-positive, unresectable or metastatic gastroesophageal adenocarcinoma. The drug can be used with tislelizumab and chemotherapy, or with chemotherapy alone for certain patients. In the Phase III HERIZON-GEA-01 trial, Ziihera-based regimens reduced the risk of disease progression or death by 35%. The triplet regimen extended median overall survival to 26.4 months, a 28% reduction in death risk versus trastuzumab. Jazz estimates the US addressable market at 3,000–4,000 patients annually and raised Ziihera's peak sales outlook to $3 billion–$5 billion. The company plans to leverage existing commercial infrastructure whilst pursuing additional cancer indications and international regulatory filings.

Yahoo Finance
Aug 11th, 2026
Jazz Pharmaceuticals Q2 revenue beats estimates at $1.21B, ups guidance to $4.68B

Jazz Pharmaceuticals reported a strong second quarter with revenue of $1.21 billion, beating analyst estimates of $1.12 billion and representing 15.5% year-on-year growth. The company raised its full-year revenue guidance to $4.68 billion from $4.38 billion. CEO Renée Galá attributed the performance to strong demand for flagship products like Xywav and Epidiolex, alongside accelerating uptake of new oncology therapies. Operating margin improved to 20.5%, up from negative 65.6% in the prior year quarter. However, adjusted earnings per share of $5.71 missed analyst expectations of $6.18. During the earnings call, analysts focused on Epidiolex's growth drivers, Xywav's sustainability amid potential generic competition, and zanidatamab's upcoming approval prospects.